Rifampicinによる肺結核治療成績

DOI Web Site PubMed

書誌事項

タイトル別名
  • CLINICAL EFFECTS OF RIFAMPICIN FOR PULMONARY TUBERCULOSIS PATIENTS
  • Rifampicin ニ ヨル ハイケッカク チリョウ セイセキ 1 ショカイ チリョウレイ ニ タイスル RFP EB INH ヘイヨウ ト SM PAS INH ヘイヨウ ト ノ コウカ ノ ヒカク
  • 1. Comparison of Rifampicin-Ethambutol-Isoniazid with Streptomycin-Paraaminosalcylic acid-Isoniazid in the Original Treatment of Pulmonary Tuberculosis Patients
  • 第1報初回治療例に対するRFP・EB・INH併用とSM・PAS・INH併用との効果の比較

この論文をさがす

説明

A controlled trial on the clinical effects of Rifampicin (RFP). Ethambutol (EB). Isoniazid (INH) tripple combination and that of Streptomycin (SM) . Paraaminosalcyclic acid (PAS). INH tripple combination was conducted on 122 previously untreated pulmonary tuberculosis (TB)patients admitted to 29 prefectural and municipal TB hospitals all over Japan.<BR>Newly diagnosed, previously untreated pulmonary TB patients with p o sitive tubercle bacilli in sputa were allocated at random to one of the above two regimens: 62 patients in RFP⋅EB⋅INH group and 60 patients in SM⋅PAS⋅INH group at the beginning of treatment.<BR>The background factors of patients in each group were almost similar except for a slight advantage of SM⋅PAS⋅INH group in regard to younger age and less extensive lesions.<BR>Dose of drugs used was as follows: 450 mg of RFP once daily before br e akfast or in 3divided dose after each meal, 750 mg of EB once daily or in 3 divided dose after each meal, 400 mg of INH once daily, 10 gram of PAS in 3 divided dose daily, orally, and 1 gram of SM twice weekly or daily, intramuscularly.<BR>The clinical effects a nd side effects of both groups were compared. Sputum negative conversion rate on culture was 67.8, 94.7 and 98.1% at 2, 4, and 6 months in RFP⋅EB⋅INH group, while the rate was 60.3, 86.8 and 96.1% in SM⋅PAS⋅INH group, respectively.<BR>The improvement of basic lesions on chest radiograms was observed in 44.1, 80.7 and 98.1%of patients at 2, 4 and 6 months in RFP⋅EB⋅INH group, while in 45.8, 83.6 and 94.3% in SM⋅PAS⋅INH group, respectively. The improvement of cavities was seen in 37.8, 61.6 an d 82.7% at 2, 4 and 6 months in RFP⋅EB⋅INH group, while in 44.9, 72, 6 and 82.9% in SM. PAS. INH group, respectively.<BR>The frequency of major side effects in each group was almost similar, but minor side effects were seen slightly more frequently in SM⋅PAS⋅INH group. Five patients in RFP⋅EB⋅INH group were dropped out through allergic reactions (2 patients), elevation of S-GOT and S-GPT values (2 patients) and optic neuropathy (1 patient), while 4 patients in SM⋅PAS⋅INH group through allergic reactions (1 patient), hearing impairment (1 patient), headache (1patient) and gastrointestinal symptoms (1 patient).<BR>It is concluded that RFP⋅EB⋅INH tripple combination is as good as SM⋅PAS⋅INH tripple combination in the original treatment of pulmonary tuberculosis.

収録刊行物

  • 結核

    結核 46 (10), 393-399, 1971

    一般社団法人 日本結核病学会

詳細情報 詳細情報について

問題の指摘

ページトップへ